The challenge of cholestatic pruritus

Acta Gastro-Enterologica Belgica

Volumn 75, Issue 4, 2012, Pages 399-404

  Bolier, A R ^a   Peri, S ^a   Oude Elferink, R P J ^a   Beuers, Ulrich ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Autotaxin; Bile salts; Cholestasis; Itch; Pruritus; Rifampicin

Indexed keywords

NALTREXONE; RIFAMPICIN; SERTRALINE; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; ANION EXCHANGE RESIN; ANTIPRURITIC AGENT; COLESTYRAMINE; ENZYME INHIBITOR; NARCOTIC ANTAGONIST; PHOSPHODIESTERASE; SEROTONIN UPTAKE INHIBITOR;

ALBUMIN DIALYSIS; CHOLESTASIS; CLINICAL OBSERVATION; DETOXIFICATION; DRUG EFFICACY; DRUG SAFETY; ENTEROHEPATIC CIRCULATION; EVIDENCE BASED PRACTICE; HUMAN; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PHOTOTHERAPY; PRURITUS; REVIEW; SYSTEMIC CIRCULATION; ULTRAVIOLET B RADIATION; DIALYSIS; DISEASE MANAGEMENT; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANION EXCHANGE RESINS; ANTIPRURITICS; CHOLESTASIS; CHOLESTYRAMINE RESIN; COMBINED MODALITY THERAPY; DIALYSIS; DISEASE MANAGEMENT; ENZYME INHIBITORS; HUMANS; NARCOTIC ANTAGONISTS; PHOSPHORIC DIESTER HYDROLASES; PHOTOTHERAPY; PROGNOSIS; PRURITUS; RIFAMPIN; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875027177     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. BENITO DE VALLE M., RAHMAN M., LINDKVIST B., BJORNSSON E., CHAPMAN R., KALAITZAKIS E. Factors That Reduce Health-Related Quality of Life in Patients With Primary Sclerosing Cholangitis. Clin. Gastro enterol. Hepatol., 2012.
2. YOUNOSSI Z.M., KIWI M.L., BOPARAI N., PRICE L.L., GUYATT G. Cholestatic liver diseases and health-related quality of life. Am. J. Gastro-enterol., 2000, 95 (2): 497-502.
3. KREMER A.E., DIJK R.V., LECKIE P., SCHAAP F.G., KUIPER E.M., METTANG T. et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. Hepatology, 2012.
4. TALWALKAR J.A., SOUTO E., JORGENSEN R.A., LINDOR K.D. Natural history of pruritus in primary biliary cirrhosis. Clin. Gastroenterol. Hepatol., 2003, 1 (4): 297-302.
5. SCHAEFER B., SCHAEFER F., WITTMER D., ENGELMANN G., WENNING D., SCHMITT C.P. Molecular Adsorbents Recirculating System dialysis in children with cholestatic pruritus. Pediatr. Nephrol., 2012, 27 (5): 829-834.
6. PARES A., HERRERA M., AVILES J., SANZ M., MAS A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J. Hepatol., 2010, 53 (2): 307-312.
7. KREMER A.E., MAILLETTE DE BUY W.L., OUDE ELFERINK R.P., BEUERS U. [Pruritus in liver disease. Pathogenesis and treatment]. Ned. Tijdschr. Geneeskd., 2011, 155 (52): A4045.
8. DECOCK S., ROELANDTS R., STEENBERGEN W.V., LALEMAN W., CASSIMAN D., VERSLYPE C. et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: An observational case series study. J. Hepatol., 2012, 57 (3): 637-641.
9. SILVEIRA M.G., LINDOR K.D. Primary sclerosing cholangitis. Can. J. Gastro enterol., 2008, 22 (8): 689-698.
10. CARBONE M., NEUBERGER J. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin. Res. Hepatol. Gastroenterol., 2011, 35 (6-7): 446-454.
11. CHAPMAN R., FEVERY J., KALLOO A., NAGORNEY D.M., BOBERG K.M., SHNEIDER B. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology, 2010, 51 (2): 660-678.
12. LINDOR K.D., GERSHWIN M.E., POUPON R., KAPLAN M., BERGASA N.V., HEATHCOTE E.J. Primary biliary cirrhosis. Hepatology, 2009, 50 (1): 291-308.
13. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol., 2009, 51 (2): 237-267.
14. AL-ALI J., AL-MUTARI N., AHMED E. Hepatitis C virus and the skin. Hepatogastroenterology, 2011, 58 (107-108): 880-886.
15. CHIA S.C., BERGASA N.V., KLEINER D.E., GOODMAN Z., HOOFNAGLE J.H., DI BISCEGLIE A.M. Pruritus as a presenting symptom of chronic hepatitis C. Dig. Dis. Sci., 1998, 43 (10): 2177-2183.
16. DORIA C., MANDALA L., SMITH J., VITALE C.H., LAURO A., GRUTTADAURIA S. et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl., 2003, 9 (4): 437-443.
17. LEBOVICS E., SEIF F., KIM D., ELHOSSEINY A., DWORKIN B.M., CASELLAS A. et al. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig. Dis. Sci., 1997, 42 (5): 1094-1099.
18. NOVELLI G., ROSSI M., POLI L., PREDAGOSTINI R., IAPPELLI M., MORABITO V. et al. Intractable pruritus in patients with hepatitis C virus. Transplant. Proc., 2006, 38 (4): 1089-1091.
19. PRINCE M.I., CHETWYND A., CRAIG W.L., METCALF J.V., JAMES O.F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut, 2004, 53 (6): 865-870.
20. GARIOUD A., SEKSIK P., CHRETIEN Y., CORPHECHOT C., POUPON R., POUPON R.E. et al. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur. J. Gastroenterol. Hepatol., 2010, 22 (7): 842-847.
21. KUIPER E.M., HANSEN B.E., METSELAAR H.J., DE MAN R.A., HAAGSMA E.B., VAN HOEK B. et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol., 2010, 10: 144.
22. MERLI L., GRIMALDI C., MONTI L., NOBILI V., FRANCALANCI P., DE VILLE DE G.J. Liver transplantation for refractory severe pruritus related to widespread multifocal hepatic focal nodular hyperplasia (FNH) in a child: Case report and review of literature. Pediatr. Transplant., 2011.
23. ABRAHAM S.C., KAMATH P.S., EGHTESAD B., DEMETRIS A.J., KRASINSKAS A.M. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am. J. Surg. Pathol., 2006, 30 (11): 1454-1461.
24. JINKS S.L., CARSTENS E. Responses of superficial dorsal horn neurons to intradermal serotonin and other irritants: comparison with scratching behavior. J. Neurophysiol., 2002, 87 (3): 1280-1289.
25. OUDE ELFERINK R.P., KREMER A.E., MARTENS J.J., BEUERS U.H. The molecular mechanism of cholestatic pruritus. Dig. Dis., 2011, 29 (1): 66-71.
26. LAMOTTE R.H., SHIMADA S.G., SIKAND P. Mouse models of acute, chemical itch and pain in humans. Exp. Dermatol., 2011, 20 (10): 778-782.
27. INAN S., COWAN A. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol. Biochem. Behav., 2006, 85 (1): 39-43.
28. BALMER M.L., DUFOUR J.F. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med. Wkly, 2008, 138 (29-30): 415-419.
29. TOROS A.B., OZERDENEN F., BEKTAS H., SARI N.D. A case report: Nasobiliary drainage inducing remission in benign recurrent intrahepatic cholestasis. Turk. J. Gastroenterol., 2012, 23 (1): 75-78.
30. SINGH V., BHALLA A., SHARMA N., DHEERENDRA P.C., AGARWAL R., MAHI S.K. Nasobiliary drainage in acute cholestatic hepatitis with pruritus. Dig. Liver Dis., 2009, 41 (6): 442-445.
31. STAPELBROEK J.M., VAN ERPECUM K.J., KLOMP LW., VENNEMAN N.G., SCHWARTZ T.P., VAN BERGE HENEGOUWEN G.P. et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology, 2006, 43 (1): 51-53.
32. DUNCAN J.S., KENNEDY H.J., TRIGER D.R. Treatment of pruritus due to chronic obstructive liver disease. Br. Med. J. (Clin. Res. Ed.), 1984, 289 (6436): 22.
33. DI PADOVA C., TRITAPEPE R., ROVAGNATI P., ROSSETTI S. Doubleblind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra-and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find. Exp. Clin. Pharmacol., 1984, 6 (12): 773-776.
34. KUIPER E.M., VAN ERPECUM K.J., BEUERS U., HANSEN B.E., THIO H.B., DE MAN R.A. et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology, 2010, 52 (4): 1334-1340.
35. EISENDLE K., MULLER H., ORTNER E., TALASZ H., GRAZIADEI I., VOGEL W. et al. Pruritus of unknown origin and elevated total serum bile acid levels in patients without clinically apparent liver disease. J. Gastroenterol. Hepatol., 2011, 26 (4): 716-721.
36. HOHENESTER S., OUDE-ELFERINK R.P., BEUERS U. Primary biliary cirrhosis. Semin. Immunopathol., 2009, 31 (3): 283-307.
37. KHURANA S., SINGH P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int., 2006, 26 (8): 943-948.
38. TANDON P., ROWE B.H., VANDERMEER B., BAIN V.G. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am. J. Gastroenterol., 2007, 102 (7): 1528-1536.
39. PRINCE M.I., BURT A.D., JONES D.E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut, 2002, 50 (3): 436-439.
40. BACHS L., PARES A., ELENA M., PIERA C., RODES J. Effects of longterm rifampicin administration in primary biliary cirrhosis. Gastroenterology, 1992, 102 (6): 2077-2080.
41. BEUERS U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol., 2006, 3 (6): 318-328.
42. FIORUCCI S., CIPRIANI S., MENCARELLI A., BALDELLI F., BIFULCO G., ZAMPELLA A. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev. Med. Chem., 2011, 11 (9): 753-762.
43. RIFAI K. Extracorporeal albumin dialysis. Hepatol. Res., 2008, 38 Suppl 1: S41-S45.
44. LECKIE P., TRITTO G., MOOKERJEE R., DAVIES N., JONES D., JALAN R. 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus. Aliment. Pharmacol. Ther., 2012, 35 (6): 696-704.
45. GAY M., PARES A., CARRASCAL M., CRESPO P., GORGA M., MAS A. et al. Proteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritus. PLoS One, 2011, 6 (7): e21850.
46. BELLMANN R., GRAZIADEI I.W., FEISTRITZER C., SCHWAIGHOFER H., STELLAARD F., STURM E. et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl., 2004, 10 (1): 107-114.
47. PARES A., CISNEROS L., SALMERON J.M., CABALLERIA L., MAS A., TORRAS A. et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol., 2004, 99 (6): 1105-1110.
48. STADLBAUER V., KRISPER P., BEUERS U., HADITSCH B., SCHNEDITZ D., JUNG A. et al. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J., 2007, 53 (2): 187-193.
49. HUSTER D., SCHUBERT C., ACHENBACH H., CACA K., MOSSNER J., BERR F. Successful clinical application of extracorporal albumin dialysis in a patient with benign recurrent intrahepatic cholestasis (BRIC). Z. Gastroenterol., 2001, 39 Suppl 2: 13-14.
50. MITZNER S.R., STANGE J., KLAMMT S., KOBALL S., HICKSTEIN H., REISINGER E.C. Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J., 2009, 55 (5): 498-502.
51. CERIO R., MURPHY G.M., SLADEN G.E., MAC DONALD D.M. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br. J. Dermatol., 1987, 116 (2): 265-267.
52. GILCHREST B.A., ROWE J.W., BROWN R.S., STEINMAN T.I., ARNDT K.A. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann. Intern. Med., 1979, 91 (1): 17-21.
53. HANID M.A., LEVI A.J. Phototherapy for pruritus in primary biliary cirrhosis. Lancet, 1980, 2 (8193): 530.
54. SCHULTZ B.C., ROENIGK H.H. Jr. Uremic pruritus treated with ultraviolet light. JAMA, 1980, 243 (18): 1836-1837.
55. LAGERSTROM M.C., ROGOZ K., ABRAHAMSEN B., PERSSON E., REINIUS B., NORDENANKAR K. et al. VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch. Neuron, 2010, 68 (3): 529-542.
56. ROSS S.E., MARDINLY A.R., MC CORD A.E., ZURAWSKI J., COHEN S., JUNG C. et al. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron, 2010, 65 (6): 886-898.
57. SCHMELZ M., SCHMIDT R., BICKEL A., HANDWERKER H.O., TOREBJORK H.E. Specific C-receptors for itch in human skin. J. Neurosci., 1997, 17 (20): 8003-8008.
58. IMAMACHI N., PARK G.H., LEE H., ANDERSON D.J., SIMON M.I., BASBAUM A.I. et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc. Natl. Acad. Sci. USA, 2009, 106 (27): 11330-11335.
59. HAN S.K., MANCINO V., SIMON M.I. Phospholipase Cbeta 3 mediates the scratching response activated by the histamine H1 receptor on C-fiber nociceptive neurons. Neuron, 2006, 52 (4): 691-703.
60. ANDREW D., CRAIG A.D. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat. Neurosci., 2001, 4 (1): 72-77.
61. YAMAMOTO-KASAI E., IMURA K., YASUI K., SHICHIJOU M., OSHIMA I., HIRASAWA T. et al. TRPV3 as a Therapeutic Target for Itch. J. Invest. Dermatol., 2012, 132 (8): 2109-2112.
62. WILSON S.R., GERHOLD K.A., BIFOLCK-FISHER A., LIU Q., PATEL K.N., DONG X. et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat. Neurosci., 2011, 14 (5): 595-602.
63. GILCHREST B.A. Pruritus: pathogenesis, therapy, and significance in systemic disease states. Arch. Intern. Med., 1982, 142 (1): 101-105.
64. MANSOUR-GHANAEI F., TAHERI A., FROUTAN H., GHOFRANI H., NASIRI-TOOSI M., BAGHERZADEH A.H. et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J. Gastroenterol., 2006, 12 (7): 1125-1128.
65. BERGASA N.V. Treatment of the Pruritus of Cholestasis. Curr. Treat. Options Gastroenterol., 2004, 7 (6): 501-508.
66. SPIVEY J.R., JORGENSEN R.A., GORES G.J., LINDOR K.D. Methionineenkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol., 1994, 89 (11): 2028-2032.
67. KREMER A.E., MARTENS J.J., KULIK W., RUEFF F., KUIPER E.M., VAN BUUREN H.R. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology, 2010, 139 (3): 1008-18, 1018.
68. MAYO M.J., HANDEM I., SALDANA S., JACOBE H., GETACHEW Y., RUSH A.J. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology, 2007, 45 (3): 666-674.
69. HASHIMOTO T., OHATA H., MOMOSE K. Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology, 2004, 72 (1): 51-56.
70. INOUE M., RASHID M.H., FUJITA R., CONTOS J.J., CHUN J., UEDA H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med., 2004, 10 (7): 712-718.
71. LIN M.E., RIVERA R.R., CHUN J. Targeted Deletion of LPA5 Identifies Novel Roles for Lysophosphatidic Acid Signaling in Development of Neuropathic Pain. J. Biol. Chem., 2012, 287 (21): 17608-17617.
72. NIETO-POSADAS A., PICAZO-JUAREZ G., LLORENTE I., JARA-OSEGUERA A., MORALES-LAZARO S., ESCALANTEALCALDE D. et al. Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site. Nat. Chem. Biol., 2012, 8 (1): 78-85.
73. PUSL T., BEUERS U. Intrahepatic cholestasis of pregnancy. Orphanet. J. Rare Dis., 2007, 2: 26.
74. LUCEY M.R., NEUBERGER J.M., WILLIAMS R. Primary biliary cirrhosis in men. Gut, 1986, 27 (11): 1373-1376.
75. LAMMERT F., MARSCHALL H.U., GLANTZ A., MATERN S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J. Hepatol., 2000, 33 (6): 1012-1021.
76. GLANTZ A., REILLY S.J., BENTHIN L., LAMMERT F., MATTSSON L.A., MARSCHALL H.U. Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology, 2008, 47 (2): 544-551.
77. VAN MIL S.W., MILONA A., DIXON P.H., MULLENBACH R., GEENES V.L., CHAMBERS J. et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology, 2007, 133 (2): 507-516.
78. YAMAMOTO Y., MOORE R., HESS H.A., GUO G.L., GONZALEZ F.J., KORACH K.S. et al. Estrogen receptor alpha mediates 17alpha-ethynyl-estradiol causing hepatotoxicity. J. Biol. Chem., 2006, 281 (24): 16625-16631.
79. TAKEO C., IKEDA K., HORIE-INOUE K., INOUE S. Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus. Endocr. J., 2009, 56 (1): 113-120.
80. KREMER AE., BEUERS U., OUDE-ELFERINK RP., PUSL T. Pathogenesis and treatment of pruritus in cholestasis. Drugs, 2008, 68 (15): 2163-2182.
81. PARK-CHUNG M., MALAYEV A., PURDY R.H., GIBBS T.T., FARB D.H. Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites. Brain Res., 1999, 830 (1): 72-87.
82. PORCU P., MOSTALLINO M.C., SOGLIANO C., SANTORU F., BERRETTI R., CONCAS A. Long-term administration with levonorgestrel decreases allopregnanolone levels and alters GABA (A) receptor subunit expression and anxiety-like behavior. Pharmacol. Biochem. Behav., 2012.
83. WU F.S., GIBBS T.T., FARB D.H. Inverse modulation of gamma-amino-butyric acid-and glycine-induced currents by progesterone. Mol. Pharma-col., 1990, 37 (5): 597-602.
84. WEAVER C.E. JR., MAREK P., PARK-CHUNG M., TAM S.W., FARB D.H. Neuroprotective activity of a new class of steroidal inhibitors of the Nmethyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA, 1997, 94 (19): 10450-10454.
85. WETZEL CH., HERMANN B., BEHL C., PESTEL E., RAMMES G., ZIEGLGANSBERGER W. et al. Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol. Endocrinol., 1998, 12 (9): 1441-1451.
86. CHEN S.C., LIU B.C., CHEN C.W., WU F.S. Intradermal pregnenolone sulfate attenuates capsaicin-induced nociception in rats. Biochem. Biophys. Res. Commun., 2006, 349 (2): 626-633.
87. GREEN A.D., YOUNG K.K., LEHTO S.G., SMITH S.B., MOGIL J.S. Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. Pain, 2006, 124 (1-2): 50-58.
88. REDDY D.S., ROGAWSKI M.A. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics, 2009, 6 (2): 392-401.
89. SCHULE C., ESER D., BAGHAI T.C., NOTHDURFTER C., KESSLER J.S., RUPPRECHT R. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience, 2011, 191: 55-77.
90. RUPPRECHT R. Neuroactive steroids: mechanisms of action and neuro-psychopharmacological properties. Psychoneuroendocrinology, 2003, 28 (2): 139-168.
91. FRYE C.A., DUNCAN J.E. Progesterone metabolites, effective at the GABAA receptor complex, attenuate pain sensitivity in rats. Brain Res., 1994, 643 (1-2): 194-203.
92. GOODCHILD C.S., KOLOSOV A., GENG L., WINTER L.L., NADESON R. Prevention and reversal of morphine tolerance by the analgesic neuroactive steroid alphadolone. Pain Med., 2009, 10 (5): 890-901.
93. SUN L.S. Gender differences in pain sensitivity and responses to analgesia. J. Gend. Specif. Med., 1998, 1 (1): 28-30.
94. LAWSON K.P., NAG S., THOMPSON A.D., MOKHA S.S. Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia. Pain, 2010, 151 (3): 806-815.